LIVIVO - Search results -

Search results

Result 1 - 10 of total 97

Search options

Book: A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials

Ferris, Steven H.

results of the instrument development project of the Alzheimer's disease cooperative study

(Alzheimer disease and associated disorders ; 11, Suppl. 2)

1997

Author's details	guest ed. Steven H. Ferris
Series title	Alzheimer disease and associated disorders ; 11, Suppl. 2 Alzheimer disease & associated disorders
Collection	Alzheimer disease & associated disorders
Keywords	Dementia / drug therapy ; Treatment Outcome ; Outcome Assessment (Health Care)
Language	English
Size	V, S72, [36] S. : graph. Darst.
Publisher	Lippincott-Raven
Publishing place	Philadelphia, PA
Publishing country	United States
Document type	Book
HBZ-ID	HT007751771
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 2569 -11,Suppl.2-	not available for loan	Zeitschriften-Lesesaal

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Experimental Aspects of Measuring the Vial Heat Transfer Coefficient in Pharmaceutical Freeze-Drying.

Wegiel, Lindsay A / Ferris, Steven J / Nail, Steven L

AAPS PharmSciTech

2018 Volume 19, Issue 4, Page(s) 1810–1817

Abstract: One of the current methods for cycle optimization in primary drying to is develop a graphical design space based on quality by design (QbD). In order to construct the design space, the vial heat transfer coefficient ( ... ...

Abstract	One of the current methods for cycle optimization in primary drying to is develop a graphical design space based on quality by design (QbD). In order to construct the design space, the vial heat transfer coefficient (K
MeSH term(s)	Desiccation/methods ; Drug Packaging/methods ; Drug Packaging/standards ; Freeze Drying/methods ; Glass/chemistry ; Hot Temperature ; Technology, Pharmaceutical/methods
Language	English
Publishing date	2018-04-03
Publishing country	United States
Document type	Journal Article
ISSN	1530-9932
ISSN (online)	1530-9932
DOI	10.1208/s12249-018-0998-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.

Ferris, Steven H / Farlow, Martin

Clinical interventions in aging

2013 Volume 8, Page(s) 1007–1014

Abstract: Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language ... ...

Abstract	Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.
MeSH term(s)	Alzheimer Disease/complications ; Cholinesterase Inhibitors/therapeutic use ; Communication Disorders/drug therapy ; Communication Disorders/physiopathology ; Donepezil ; Galantamine/therapeutic use ; Humans ; Indans/therapeutic use ; Outcome Assessment, Health Care ; Phenylcarbamates/therapeutic use ; Piperidines/therapeutic use ; Rivastigmine
Chemical Substances	Cholinesterase Inhibitors ; Indans ; Phenylcarbamates ; Piperidines ; Galantamine (0D3Q044KCA) ; Donepezil (8SSC91326P) ; Rivastigmine (PKI06M3IW0)
Language	English
Publishing date	2013-08-02
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2364924-0
ISSN	1178-1998 ; 1176-9092
ISSN (online)	1178-1998
ISSN	1176-9092
DOI	10.2147/CIA.S39959
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6742: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Supplement editorial: alzheimer disease.

Ferris, Steven H

Alzheimer disease and associated disorders

2006 Volume 20, Issue 4 Suppl 3, Page(s) S107–8

MeSH term(s)	Aged ; Alzheimer Disease/diagnosis ; Alzheimer Disease/epidemiology ; Alzheimer Disease/prevention & control ; Humans ; Neuropsychological Tests ; Population Dynamics ; Primary Prevention
Language	English
Publishing date	2006-10
Publishing country	United States
Document type	Editorial
ZDB-ID	1002700-2
ISSN	1546-4156 ; 0893-0341
ISSN (online)	1546-4156
ISSN	0893-0341
DOI	10.1097/01.wad.0000213875.63171.87
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2569: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: General measures of cognition.

Ferris, Steven H

International psychogeriatrics

2003 Volume 15 Suppl 1, Page(s) 215–217

Abstract: A general cognitive performance battery is needed as a primary outcome in vascular dementia clinical trials. Because there is considerable overlap between vascular dementia and Alzheimer's disease (AD) in the pattern of cognitive impairment, a reasonable ...

Abstract	A general cognitive performance battery is needed as a primary outcome in vascular dementia clinical trials. Because there is considerable overlap between vascular dementia and Alzheimer's disease (AD) in the pattern of cognitive impairment, a reasonable approach to developing an optimal vascular dementia battery is to begin with a widely used AD measure and improve its sensitivity to the cognitive domains that are more prominent in vascular dementia. Thus the VaDAS-cog has evolved, which comprises the ADAS-cog with additional frontal lobe subtests covering attention, working memory, executive function, and verbal fluency. Validation of this new cognitive instrument will be supported by its successful use in vascular dementia clinical trials.
MeSH term(s)	Aged ; Alzheimer Disease/complications ; Alzheimer Disease/pathology ; Cognition Disorders/diagnosis ; Cognition Disorders/etiology ; Dementia, Vascular/complications ; Dementia, Vascular/pathology ; Frontal Lobe/pathology ; Humans ; Neuropsychological Tests ; Reproducibility of Results
Language	English
Publishing date	2003
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, P.H.S. ; Validation Studies
ZDB-ID	1038825-4
ISSN	1741-203X ; 1041-6102
ISSN (online)	1741-203X
ISSN	1041-6102
DOI	10.1017/S1041610203009220
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2621: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 513: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Evaluation of memantine for the treatment of Alzheimer's disease.

Ferris, Steven H

Expert opinion on pharmacotherapy

2003 Volume 4, Issue 12, Page(s) 2305–2313

Abstract: Increasing evidence suggests that disturbances in glutamatergic activity play an important role in Alzheimer's disease (AD). Excessive glutamate-mediated activation of NMDA receptors, for example, may contribute to the neuronal death that characterises ... ...

Abstract	Increasing evidence suggests that disturbances in glutamatergic activity play an important role in Alzheimer's disease (AD). Excessive glutamate-mediated activation of NMDA receptors, for example, may contribute to the neuronal death that characterises AD. On the other hand, physiological activation of the NMDA receptor appears necessary for normal cognitive function. Therefore, compounds that finely modulate NMDA receptor activity hold promise as treatments for AD. Memantine (Namenda, Axura, Ebixa; Forest Laboratories, Inc., Merz Pharmaceuticals GmbH, H. Lundbeck A/S) is a low-moderate affinity, uncompetitive NMDA-receptor antagonist that appears to block pathological, but not physiological, activation of the NMDA receptor. Consequently, therapeutic doses of the drug are well-tolerated and do not seem to interfere with the acquisition or processing of cognitive information. Memantine has been shown to improve symptoms and reduce the rate of clinical deterioration among patients with moderate-to-severe AD and was approved in the US for this indication in October 2003. This review provides a brief rationale for the development of memantine as a therapy for AD, as well as an overview of the pharmacology, clinical efficacy, safety and tolerability of this novel therapeutic agent.
MeSH term(s)	Alzheimer Disease/drug therapy ; Alzheimer Disease/economics ; Antiparkinson Agents/adverse effects ; Antiparkinson Agents/pharmacology ; Antiparkinson Agents/therapeutic use ; Clinical Trials as Topic ; Cost-Benefit Analysis ; Humans ; Memantine/adverse effects ; Memantine/pharmacology ; Memantine/therapeutic use
Chemical Substances	Antiparkinson Agents ; Memantine (W8O17SJF3T)
Language	English
Publishing date	2003-08-15
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2001535-5
ISSN	1465-6566
ISSN	1465-6566
DOI	10.1517/14656566.4.12.2305
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5130: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Clinical trials in AD: are current formats and outcome measures adequate?

Ferris, Steven H

Alzheimer disease and associated disorders

2002 Volume 16 Suppl 1, Page(s) S13–7

Abstract: Great strides have been made in the measurement of outcomes and treatment efficacy in clinical trials of Alzheimer disease (AD) drugs during the past 25 years. Several sensitive, reliable, and valid clinical outcome measures have been developed. The ... ...

Abstract	Great strides have been made in the measurement of outcomes and treatment efficacy in clinical trials of Alzheimer disease (AD) drugs during the past 25 years. Several sensitive, reliable, and valid clinical outcome measures have been developed. The methodology, trial design, and outcome measures for demonstrating symptomatic benefits of an AD drug are now established. However, a greater challenge lies ahead. Major advances in fundamental knowledge about the pathophysiology of the disease and in animal models have transformed the focus of current efforts to developing and testing therapies that may actually slow disease progression, delay the onset of symptoms, and even ultimately prevent the disease. The long-duration trials that will likely be necessary to demonstrate an effect on disease progression will be costly and difficult. Proof-of-concept trials and subsequent long-term trials could gain power and efficiency from use of biologic markers of underlying disease severity, but currently available biologic markers are not ideal. A major barrier to such trials is their size and cost. One approach to reducing the cost would be to recruit "enriched" samples of subjects who are at greater risk of developing AD during the trial than the general, elderly population. The major effort required to screen and recruit large numbers of subjects for such trials also contributes to the cost. Probably the biggest problem currently is the enormous effort and cost of conducting periodic clinical evaluations to determine if subjects have declined or developed dementia. Research to develop more efficient assessment methods is clearly needed. Data acquisition over the Internet is potentially efficient and attractive and may become practical as Internet accessibility increases.
MeSH term(s)	Alzheimer Disease/drug therapy ; Animals ; Clinical Trials as Topic/methods ; Humans ; Outcome Assessment (Health Care)/methods
Language	English
Publishing date	2002-06-09
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1002700-2
ISSN	1546-4156 ; 0893-0341
ISSN (online)	1546-4156
ISSN	0893-0341
DOI	10.1097/00002093-200200001-00003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2569: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.

Isaacson, Richard S / Ferris, Steven / Velting, Drew M / Meng, Xiangyi

American journal of Alzheimer's disease and other dementias

2015 Volume 31, Issue 3, Page(s) 270–277

Abstract: Severe Impairment Battery (SIB) data from the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study suggest that patients with severe Alzheimer's disease (AD) benefit from treatment with 13.3 versus 4.6 mg/24 h ... ...

Abstract	Severe Impairment Battery (SIB) data from the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study suggest that patients with severe Alzheimer's disease (AD) benefit from treatment with 13.3 versus 4.6 mg/24 h rivastigmine patch. The objective of this retrospective analysis was to further examine the cognitive efficacy of 13.3 versus 4.6 mg/24 h rivastigmine patch on individual SIB items, and SIB domains derived using factor analysis of these items. Change from baseline at Week 24 on 9 new factor-defined domains and individual items was calculated and compared using effect sizes (Cohen's d). Numerically less decline was observed with 13.3 versus 4.6 mg/24 h patch on all domains and the majority of individual items. Largest least squares mean treatment differences were observed on "visuospatial reasoning," "object naming," "recognition," "design copying," "social agency," "ideational praxis," and "comprehension" domains. These findings suggest 13.3 mg/24 h rivastigmine patch demonstrates broad cognitive efficacy across a range of SIB items and domains in patients with severe AD.
MeSH term(s)	Activities of Daily Living ; Aged ; Aged, 80 and over ; Alzheimer Disease/complications ; Alzheimer Disease/drug therapy ; Cholinesterase Inhibitors/administration & dosage ; Cholinesterase Inhibitors/pharmacology ; Cognition Disorders/drug therapy ; Cognition Disorders/etiology ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Retrospective Studies ; Rivastigmine/administration & dosage ; Rivastigmine/pharmacology ; Severity of Illness Index ; Transdermal Patch
Chemical Substances	Cholinesterase Inhibitors ; Rivastigmine (PKI06M3IW0)
Language	English
Publishing date	2015-09-14
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1283069-0
ISSN	1938-2731 ; 0895-5336 ; 1082-5207 ; 1533-3175
ISSN (online)	1938-2731
ISSN	0895-5336 ; 1082-5207 ; 1533-3175
DOI	10.1177/1533317515603687
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3299: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis.

Ferris, Steven / Karantzoulis, Stella / Somogyi, Monique / Meng, Xiangyi

Alzheimer's research & therapy

2013 Volume 5, Issue 6, Page(s) 63

Abstract: Introduction: The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, ...

Abstract	Introduction: The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, in patients with moderately severe-to-severe Alzheimer's disease (AD). Methods: This was a retrospective analysis of a 26-week, multicenter, randomized, double-blind, placebo-controlled study of oral rivastigmine conducted in Spain. Previously reported outcome measures included the full SIB. Current analyses examined calculated scores and effect sizes for the change from baseline at Week 26 on: newly defined SIB subscales (derived by a factor analysis of the 40 SIB items, using the PROC FACTOR function (SAS)); previously defined memory, language and praxis subscales (derived by previous analysis of the nine SIB domains); and the individual SIB items. Treatment differences were assessed. Results: SIB data were provided by 104 rivastigmine-treated patients and 106 patients receiving placebo (Intent-To-Treat Last Observation Carried Forward population). Significantly less decline was observed on the previously defined memory and language subscales, and the newly defined working memory/memory subscale in rivastigmine-treated patients (all P < 0.05 versus placebo). Calculation of effect sizes demonstrated numerically greater efficacy of rivastigmine versus placebo on each of the subscales, and a broad range of SIB items; greatest effect sizes were observed on SIB items assessing the current month (effect size = 0.30) and digit span series (effect size = 0.33). Conclusions: These data suggest the observed efficacy of rivastigmine in moderately severe-to-severe AD is likely a cumulative effect across a range of tasks. Rivastigmine demonstrates broad cognitive efficacy in this patient population.
Language	English
Publishing date	2013-12-18
Publishing country	England
Document type	Journal Article
ZDB-ID	2506521-X
ISSN	1758-9193
ISSN	1758-9193
DOI	10.1186/alzrt229
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults.

Li, Clara / Neugroschl, Judith / Luo, Xiaodong / Zhu, Carolyn / Aisen, Paul / Ferris, Steven / Sano, Mary

Journal of Alzheimer's disease : JAD

2017 Volume 60, Issue 2, Page(s) 427–437

Abstract: Background: Subjective cognitive complaint is a sensitive marker of decline.: Objective: This study aimed to (1) examine reliability of subjective cognitive complaint using the Cognitive Function Instrument (CFI), and (2) assess the utility of the ... ...

Abstract	Background: Subjective cognitive complaint is a sensitive marker of decline. Objective: This study aimed to (1) examine reliability of subjective cognitive complaint using the Cognitive Function Instrument (CFI), and (2) assess the utility of the CFI to detect cognitive decline in non-demented elders. Methods: Data from a four-year longitudinal study at multiple Alzheimer's Disease Cooperative Study (ADCS) sites were extracted (n = 644). Of these, 497 had Clinical Dementia Rating (CDR) global scores of 0 and 147 had a CDR of 0.5. Mean age and education were 79.5±3.6 and 15.0±3.1 years, respectively. All participants and their study partners completed the subject and study partner CFI yearly. Modified Mini-Mental State Exam (mMMSE) and Free and Cued Selective Reminding Test (FCSRT) were administered. Scores below the predetermined cut-off scores on either measure at annual visit were triggers for a full diagnostic evaluation. Cognitive decline was defined by the absence/presence of the trigger. Results: Three-month test retest reliability showed that inter-class coefficients for subject and study partner CFI were 0.76 and 0.78, respectively. Generalized estimating equation method revealed that both subject and study partner CFI change scores and scores from previous year were sensitive to cognitive decline in the CDR 0 group (p < 0.05). In the CDR 0.5 group, only the study partner CFI change score predicted cognitive decline (p < 0.05). Conclusion: Cognitive decline was predicted differentially by CDR level with subject CFI scores providing the best prediction for those with CDR 0 while study partner CFI predicted best for those at CDR 0.5.
MeSH term(s)	Aged ; Aged, 80 and over ; Aging/psychology ; Cognition ; Cognitive Dysfunction/physiopathology ; Cognitive Dysfunction/psychology ; Female ; Humans ; Male ; Mental Status and Dementia Tests ; Neuropsychological Tests ; Reproducibility of Results ; Surveys and Questionnaires
Language	English
Publishing date	2017-08-31
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1440127-7
ISSN	1875-8908 ; 1387-2877
ISSN (online)	1875-8908
ISSN	1387-2877
DOI	10.3233/JAD-161294
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6084: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito